Uncontrolled urbanization led to a specific environment, promoting the spread of Aedes mosquitoes in many African cities. The objective of the study was to assess human exposure to Aedes mosquito bites in the urban area of Abidjan, Côte d’Ivoire, by using antibody-based biomarkers. A cross-sectional study was undertaken during the short rainy season in 3 different neighborhoods (Bromakote, Anoumabo, and Petit-Bassam) presenting various socio-environmental and entomological characteristics. The specific IgG responses to Aedes Nterm-34kDa salivary peptide, previously validated as a relevant individual biomarker of exposure to mosquito bites, were assessed in children and analyzed according to neighborhoods and age classes. The specific IgG level was significantly different according to the 3 neighborhoods and higher in Bromakote compared to Anoumabo and Petit-Bassam. No significant difference in specific IgG level was observed according to age. We also noticed an association between the level of specific IgG responses and Ae. aegypti densities or various socio-environmental factors. This study indicated that Human exposure to Aedes vector appeared to be dependent on neighborhoods within the same city, which could be related to some socio-environmental factors. Antibody-based biomarkers of human exposure to Aedes bites could be a helpful tool for assessing the heterogeneity of urban exposure to arbovirus vectors in the framework of monitoring the risk of arbovirus infections, and for evaluating the effectiveness of vector control strategies in national control programs.

The authors have declared no competing interest.

This research was integrated into the ARBORISK multidisciplinary study funded through the C2D program (Contrat de Desendettement et de Developpement; 2013). BZH Zamble was supported by a PhD fellowship provided by the Mediterannee Infection Foundation. DD Zoh was supported by a fellowship from the IRD.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The protocol was approved by the Ethics Committee of Côte d’Ivoire, Ministry of Health (June 2014; N° 41/MSLS/CNER-dkn).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors